Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic Hematopoietic Cell Transplantation with Post Transplant Cyclophosphamide As Gvhd Prophylaxis

Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Filippo Milano, Claudio G. Brunstein, Cara L. Benjamin, Navneet S. Majhail, Stephen R. Spellman, Corey S. Cutler

Blood (2022) 140 (Supplement 1): 895–896.

https://doi.org/10.1182/blood-2022-167736

Published: 2022

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Blood (2022) 140 (Supplement 1): 8019–8021.

https://doi.org/10.1182/blood-2022-167411

Published: 2022

Journal Articles

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Rajshekhar Chakraborty, Tapas Ranjan Behera, Hong Li, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Allison Winter, Faiz Anwer, Brad Pohlman, Ronald M. Sobecks, Betty K. Hamilton, Navneet S. Majhail

Blood (2022) 140 (Supplement 1): 10926–10927.

https://doi.org/10.1182/blood-2022-166904

Published: 2022

Journal Articles

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Blood (2021) 138 (26): 2781–2798.

https://doi.org/10.1182/blood.2021012900

Published: 2021

Includes: Supplemental data

Journal Articles

Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial

Navneet S. Majhail, Beckley Miller, Rebecca Dean, Rocio Manghani, Smitha Sivaraman, Einat Galamidi-Cohen, Richard T. Maziarz

Blood (2021) 138 (Supplement 1): 4036.

https://doi.org/10.1182/blood-2021-147480

Published: 2021

Journal Articles

Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant

Lauren M. Granat, Lisa A. Rybicki, Mailey L. Wilks, Christina Ferraro, Matt Kalaycio, Ronald M. Sobecks, Navneet S. Majhail, Dana E. Angelini, Betty K. Hamilton

Blood (2021) 138 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2021-151230

Published: 2021

Journal Articles

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 99.

https://doi.org/10.1182/blood-2021-149686

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans

Rajshekhar Chakraborty, Lisa A. Rybicki, Jaime M. Preussler, Steven Devine, K. Scott Baker, Karen Syrjala, Jean C. Yi, Jennifer L Whitten, Bronwen E. Shaw, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 431.

https://doi.org/10.1182/blood-2021-149281

Published: 2021

Journal Articles

Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients

Zeina Al-Mansour, Sanghee Hong, Nosha Farhadfar, Jing Zhao, Ji-Hyun Lee, Bronwen E. Shaw, Steven Devine, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Karen Syrjala, Navneet S. Majhail, John R. Wingard

Blood (2021) 138 (Supplement 1): 426.

https://doi.org/10.1182/blood-2021-151037

Published: 2021

Journal Articles

Community Health Status and Long-Term Outcomes in 1-Year Survivors of Autologous and Allogeneic Hematopoietic Cell Transplantation

Julia H. Joo, Sanghee Hong, Lisa A. Rybicki, Betty K. Hamilton, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 422.

https://doi.org/10.1182/blood-2021-148035

Published: 2021

Journal Articles

Germline Biallelic Loss in MBD4 leading to Early Onset AML with Hyper-Mutator Genomic Signature

Brittany L Griffin, Navneet S. Majhail, Harry Lesmana

Blood (2021) 138 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2021-154221

Published: 2021

Journal Articles

Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors

Sanghee Hong, Jing Zhao, Ji-Hyun Lee, Nosha Farhadfar, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Bronwen E. Shaw, Steven Devine, Karen Syrjala, John R. Wingard, Navneet S. Majhail, Zeina Al-Mansour

Blood (2021) 138 (Supplement 1): 4123.

https://doi.org/10.1182/blood-2021-145428

Published: 2021

Journal Articles

Immunogenetic Drivers in Post-Transplant Acute Myeloid Leukemia Recurrence: Genomic Dysfunction of Human Leukocyte Antigen Diversity

Simona Pagliuca, Carmelo Gurnari, Laila Terkawi, Ishani Pandit, Tariq Kewan, Waled Bahaj, Minako Mori, Suresh Kumar Balasubramanian, Ashwin Kishtagari, Hetty E. Carraway, Betty K. Hamilton, Navneet S. Majhail, Valeria Visconte, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2021-153577

Published: 2021

Journal Articles

Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors

Nosha Farhadfar, Michael Weaver, Zeina Al-Mansour, Jean C. Yi, Heather S. L. Jim, Alison W. Loren, Navneet S. Majhail, Victoria Whalen, John R. Wingard, Debra Lynch Kelly, Karen Syrjala

Blood (2021) 138 (Supplement 1): 3932.

https://doi.org/10.1182/blood-2021-147968

Published: 2021

Journal Articles

Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis

Brandon J. Blue, Ruta Brazauskas, Karen Chen, Shahrukh Hashmi, Leslie E. Lehmann, William A. Wood, Navneet S. Majhail, Wael Saber

Blood (2021) 138 (Supplement 1): 3929.

https://doi.org/10.1182/blood-2021-153357

Published: 2021

Journal Articles

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Blood (2021) 137 (4): 556–568.

https://doi.org/10.1182/blood.2020006252

Published: 2021

Includes: Supplemental data

Journal Articles

Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations

Simona Pagliuca, MD, Carmelo Gurnari, MD, Sanghee Hong, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Hassan Awada, MD, Ashwin Kishtagari, MBBS, Misam Zawit, MBBS, Laila Terkawi, Valeria Visconte, PhD, Eric D. Hsi, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-143242

Published: 2020

Journal Articles

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Carlos Bachier, MD, Gautam Borthakur, MD, Chitra Hosing, MD, William Blum, MD, Marcello Rotta, MD, Paulius Ojeras, Brian Barnett, MD, Kanya Rajangam, MD PhD, Navneet S. Majhail, MD MS, Sarah Nikiforow, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-134625

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic Hematopoietic Cell Transplantation with Post Transplant Cyclophosphamide As Gvhd Prophylaxis

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial

Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans

Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients

Community Health Status and Long-Term Outcomes in 1-Year Survivors of Autologous and Allogeneic Hematopoietic Cell Transplantation

Germline Biallelic Loss in MBD4 leading to Early Onset AML with Hyper-Mutator Genomic Signature

Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors

Immunogenetic Drivers in Post-Transplant Acute Myeloid Leukemia Recurrence: Genomic Dysfunction of Human Leukocyte Antigen Diversity

Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors

Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only